SCHEMBL3499356

SCHEMBL3499356

Cc1cc(-c2ccc(Cl)cc2)cn2cc(C(=O)O)nc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.58
GABRA2 P47869 1/20 0.48
GABRB2 P47870 1/20 0.48
SMN1; SMN2 Q16637 4/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
MAPT P10636 1/20 0.43
AHR P35869 1/20 0.43
EGLN1 Q9GZT9 1/20 0.43
PPP1CA P62136 2/20 0.42
MCL1 Q07820 1/20 0.42
KDM4E B2RXH2 2/20 0.41
RPA1 P27694 2/20 0.41
ALDH1A1 P00352 1/20 0.41
PKM P14618 1/20 0.41
KMO O15229 1/20 0.40
DHODH Q02127 3/20 0.40
CTRC Q99895 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3500116 0.84 GABRA2 (0.57) GABRA2GABRB2MAPTKDM4EALDH1A1
SCHEMBL3498537 0.76 EGLN1 (0.67) GABRA2GABRB2NPC1RAB9AEGLN1
SCHEMBL3498341 0.75 GABRA2 (0.47) RXFP1GABRA2GABRB2SMN1; SMN2NPC1
SCHEMBL23571819 0.74 RXFP1 (1.00) RXFP1SMN1; SMN2RAB9AMAPTEGLN1
SCHEMBL13330782 0.74 RXFP1 (0.68) RXFP1GABRA2GABRB2SMN1; SMN2RAB9A
SCHEMBL3500124 0.72 GRM5 (0.53) GABRA2GABRB2SMN1; SMN2EGLN1PPP1CA
SCHEMBL3498830 0.72 PTGS1 (0.51) GABRA2GABRB2SMN1; SMN2NPC1RAB9A
SCHEMBL312204 0.72 RAB9A (0.45) SMN1; SMN2NPC1RAB9AMAPTAHR
SCHEMBL23534255 0.71 RXFP1 (0.64) RXFP1SMN1; SMN2NPC1RAB9AMAPT
SCHEMBL15071114 0.71 NPC1 (0.53) RXFP1SMN1; SMN2NPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
EP-1849465-A1 AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR Takeda Pharmaceutical Company Limited (JP) 2007-10-31 EP disclosed
EP-1849465-A1 AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR Takeda Pharmaceutical Company Limited (JP) 2007-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function GPR34, GPR4, GPR6 RXFP1 90/4885GABRA2 317/4885GABRB2 169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.